Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.760
Open
1.720
VWAP
1.73
Vol
91.84K
Mkt Cap
76.79M
Low
1.720
Amount
159.12K
EV/EBITDA(TTM)
--
Total Shares
44.36M
EV
-44.21M
EV/OCF(TTM)
--
P/S(TTM)
--
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.189
-5.35%
--
--
-0.170
+5.83%
--
--
-0.160
+14.88%
Estimates Revision
The market is revising No Change the revenue expectations for ESSA Pharma Inc. (EPIX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 2.37%.
EPS Estimates for FY2025
Revise Upward
+53.63%
In Past 3 Month
Stock Price
Go Up
+2.37%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for ESSA Pharma Inc (EPIX.O) is -2.54, compared to its 5-year average forward P/E of -7.43. For a more detailed relative valuation and DCF analysis to assess ESSA Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.43
Current PE
-2.54
Overvalued PE
-1.41
Undervalued PE
-13.45
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.64
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.63
Undervalued EV/EBITDA
-11.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.83
Current PS
0.00
Overvalued PS
6.66
Undervalued PS
-5.01
Financials
Annual
Quarterly
FY2025Q1
YoY :
+27.52%
-9.68M
Operating Profit
FY2025Q1
YoY :
+43.05%
-8.53M
Net Income after Tax
FY2025Q1
YoY :
+35.71%
-0.19
EPS - Diluted
FY2025Q1
YoY :
-4.67%
-6.47M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 287078.23% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
12.0M
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 13851.93% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
4.2M
Volume
2
6-9
Months
0.0
Volume
0
0-12
Months
30.0K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
1.2M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 287078.23% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
12.0M
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
EPIX News & Events
Events Timeline
2025-02-11 (ET)
2025-02-11
06:08:22
Essa Pharma reports Q4 EPS (19c) vs. (14c) last year
2024-12-17 (ET)
2024-12-17
06:04:59
Essa Pharma reports Q4 EPS (14c), consensus (27c)
2024-11-01 (ET)
2024-11-01
08:13:22
Essa Pharma terminates Phase 2 study of masofaniten combo in mCRPC
Sign Up For More Events
Sign Up For More Events
News
7.0
03-25PRnewswireESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
7.0
03-24GlobenewswireESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion
7.0
03-24PRnewswireThe Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
Sign Up For More News
People Also Watch
ARQQ
Arqit Quantum Inc
16.000
USD
+4.58%
ABSI
Absci Corp
2.660
USD
+0.38%
KRRO
Korro Bio Inc
13.930
USD
-5.85%
CERS
Cerus Corp
1.300
USD
+4.00%
RR
Richtech Robotics Inc
2.070
USD
-1.90%
HRTG
Heritage Insurance Holdings Inc
24.300
USD
+22.54%
IHRT
iHeartMedia Inc
1.100
USD
+0.92%
SES
SES AI Corp
0.823
USD
+1.73%
HVT
Haverty Furniture Companies Inc
18.810
USD
-0.21%
SEG
Seaport Entertainment Group Inc
18.830
USD
-1.77%
FAQ
What is ESSA Pharma Inc (EPIX) stock price today?
The current price of EPIX is 1.73 USD — it has increased 0.58 % in the last trading day.
What is ESSA Pharma Inc (EPIX)'s business?
What is the price predicton of EPIX Stock?
What is ESSA Pharma Inc (EPIX)'s revenue for the last quarter?
What is ESSA Pharma Inc (EPIX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ESSA Pharma Inc (EPIX)'s fundamentals?
How many employees does ESSA Pharma Inc (EPIX). have?